Stockreport

PAVmed Successfully Completes Clinical Safety Study Procedures for CarpX™ 510(k) Re-submission

PAVmed Inc.  (PAVM) 
US:NASDAQ Investor Relations: ir.pavm.com
PDF All 20 patients underwent successful CarpX procedures while passing primary effectiveness endpoint, with all follow-up patients to date passing primary safety endpoint [Read more]